GCG100649, A Novel Cyclooxygenase‐2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase‐I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies

Publisher: John Wiley & Sons Inc

E-ISSN: 2160-7648|2|4|379-386

ISSN: 2160-763X

Source: Clinical Pharmacology In Drug Development, Vol.2, Iss.4, 2013-10, pp. : 379-386

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract